Did the FDA just approve peptides for compounding, and which ones are covered?

The short answer

On 28 October 2026 the Department of Health and Human Services filed a notice announcing a draft Enforcement Discretion Policy Regarding 503A Compounding Using Certain Peptide Bulk Drug Substances. It was published in the Federal Register on 30 October 2026 under Docket No. HHS-OASH-2026-0496 and signed by the Secretary, Robert F. Kennedy Jr.

Evidence tier: Tier 1 for the regulatory facts — Federal Register notice, the HHS policy document and its appendices, FDA advisory committee records. Tier 3–4 for the clinical evidence on the peptides themselves, which is the heart of the dispute. US law only. Educational content, not legal or medical advice.

The policy covers six peptides, not five: BPC-157, Epitalon, KPV, MOTS-c, Semax and TB-500.

It is not an approval. It is a statement that HHS does not intend to take enforcement action against a state-licensed pharmacy, federal facility or licensed physician who compounds one of these six under ten specific conditions — including a route of administration fixed separately for each peptide. The document says in its own words that it "does not establish any rights for any person and is not binding on HHS or the public," and that HHS "may revisit" it if a safety signal appears.

The key points:

• Six peptides, not five. The five-peptide figure in circulation is the next advisory committee agenda, due before February 2027.
• Enforcement discretion is not approval, and not the bulks list. Compounded drugs remain un-reviewed by the FDA for safety, effectiveness or quality.
• Each peptide gets its own permitted route. Injectable KPV is not covered. Injectable Semax is not covered.
• Single active ingredient only. Blends and stacks fall outside the policy entirely.
• The FDA's own scientists recommended against all seven peptides considered. The advisory committee voted the other way, and HHS has now acted on the committee's view.
• It is a draft with a two-week comment window, closing around 13 November 2026, and it is already the subject of a citizen petition.

What HHS actually did, in order

Evidence tier: Tier 1. Regulatory facts, drawn from the Federal Register notice, the HHS policy document and FDA's published lists.

Four things are routinely collapsed into one. They are separate, and the difference decides what is lawful.

Section 503A of the Federal Food, Drug, and Cosmetic Act exempts a patient-specific compounded drug from pre-market approval, from full labeling requirements and from CGMP — but only if the bulk substance used satisfies one of three tests: it complies with a USP or NF monograph, or it is a component of an FDA-approved drug, or it appears on the 503A bulks list.

None of the six peptides satisfies any of the three. That has not changed. What changed is that HHS has said it will not enforce against the gap while the rulemaking runs.

Note also who signed it. The policy came from the Office of the Secretary, not from the FDA's Center for Drug Evaluation and Research — and CDER recommended against listing every one of these substances.

The six peptides, and the route limits nobody is reporting

Evidence tier: Tier 1. Identity, salt form and permitted route are taken from Appendices A and B of the HHS policy document.

This is the part that gets lost. Appendix A names the six substances. Appendix B fixes the identity, salt form and permitted route for each one separately, and they are not the same.

Two consequences follow immediately.

Injectable KPV is outside the policy. KPV is widely used as a subcutaneous injection in the community. The covered routes are topical and oral. An injectable KPV product is in exactly the same legal position it was in on 27 October.

Injectable Semax is outside the policy, and the salt form differs. Semax is covered as the free base, intranasal only. Every other peptide on the list is covered as the acetate. HHS's stated reason is specific: the human exposure record that CDER itself assembled for semax is an intranasal record covering several hundred subjects. The discretion follows the evidence, and the evidence is nasal.

Epitalon carries a dosing-pattern condition — intermittent courses, not continuous use — because the documented human regimens were intermittent.

The ten conditions

Evidence tier: Tier 1. The conditions are quoted from the draft policy; the statement about market effect is our reading of them.

Enforcement discretion applies only when all of the following are true. Any one missing and the policy does not apply.

1. The substance appears in Appendix A.
2. It has the identity — amino acid sequence, structure, molecular formula, molecular weight — and the route limitation in Appendix B.
3. It comes with a valid certificate of analysis from a facility registered under section 510, with results for identity, purity, potency, endotoxins, heavy metals, microbial contamination and impurities.
4. The original manufacturer, not a repacker or distributor, is FDA-registered, CGMP-compliant, and its physical address appears on the COA. A repacker in the chain must have performed and documented its own vendor validation.
5. Serious adverse events and product-quality issues are reported to FDA MedWatch, and the compounder reports the active ingredient and strength, the original manufacturer with facility identifier, and the dosage form and route.
6. Labeling carries: "This is a compounded drug product. Not for resale."
7. The product contains a single active ingredient. HHS's reason is attribution: you cannot trace an adverse event to a substance in a blend.
8. Any oral form requires documentation that that specific formulation is adequately bioavailable in humans.
9. The only co-packaged delivery device is an FDA 510(k)-cleared syringe.
10. Everything else in the FD&C Act still applies, including the ban on insanitary conditions and the patient-specific prescription requirement.

Condition 7 is the one with the widest market effect. Multi-peptide blends — BPC-157 with TB-500 being the most common pairing in our social-signal corpus — are not covered, no matter where the ingredients came from.

The FDA's scientists said no. Seven times.

Evidence tier: Tier 1 for the vote and the staff recommendations (advisory committee records). The committee-composition point rests on press reporting and is contested.

In April 2026 the FDA announced three advisory committee meetings to evaluate peptide bulk substances. At the first, on 23–24 July 2026, the Pharmacy Compounding Advisory Committee considered seven distinct peptides across fourteen entries (free base and acetate forms).

FDA staff presented on each and recommended that none be added to the 503A bulks list, citing minimal evidence of safety or effectiveness, in some cases no human effectiveness data and no toxicology at all, and risks including bleeding and carcinogenicity.

The committee voted to recommend six of the seven anyway. Emideltide (DSIP) was excluded on a 6–7 vote.

The composition of that committee is now itself contested. Several members had been newly appointed, and reporting notes that at least three own compounding pharmacies.

So what changed between July and October?

Evidence tier: Tier 1 for what HHS says its rationale is; the assessment of what that rationale does and does not show is our interpretation.

HHS gives a per-peptide answer, and it is worth reading precisely because it is narrower than the headlines suggest. For each of the six, the justification runs along the same three lines:

• The characterisation record changed. Lot-specific certificates from FDA-registered facilities now supply the endotoxin, microbial, residual-solvent and impurity results CDER had found missing. This is a manufacturing-quality argument, not a clinical one.
• Historical use is now documented and quantified, where CDER had found the extent of compounding unknown — and for TB-500, could not identify any pharmacy compounding it at all.
• CDER's safety concerns were "mechanistic rather than observed" — inferred from what the molecule does, rather than drawn from reported harm.

That third line is the crux, and it cuts both ways. An absence of observed harm in a substance with little controlled human exposure is not the same as evidence of safety. HHS's own framing concedes the point by resting on lot-level testing, single-ingredient products and MedWatch reporting as the mitigations — surveillance, in other words, rather than prior evidence.

HHS also states a displacement rationale outright: the policy is meant to "discourage the continued, widespread use of certain research-use-only peptides supplied by foreign manufacturers that pose a safety risk to US patients." The target is the grey market, and the instrument is a regulated alternative.

What the clinical evidence actually looks like

Nothing in this policy adds a single data point about whether these peptides work. The underlying evidence is unchanged, and it is thin.

Evidence tier: 3–4 — predominantly animal and in vitro. One systematic review of human use. No adequately powered efficacy RCT for any of the six in the indications people use them for.

• BPC-157 has a large rodent literature across tendon, muscle and gut injury models (PMID 16583442, PMID 21030672, PMID 22300085). The 2025 systematic review of its emerging orthopaedic use (PMID 40756949) is the honest place to start: the human record is what it finds, and what it finds is limited.
• MOTS-c is a genuinely interesting mitochondrial-derived peptide with good mechanistic work behind it (PMID 25738459, PMID 33473109). HHS's safety argument leans on a randomised placebo-controlled trial of a MOTS-c analogue — not MOTS-c itself.
• KPV, a three-amino-acid fragment of α-MSH, has coherent anti-inflammatory mechanism and murine IBD data (PMID 18061177, PMID 18092346) — which is consistent with the policy covering it topically and orally rather than by injection.
• Semax has a Russian-language clinical literature and rodent BDNF work (PMID 16635254, PMID 24661604). The intranasal human exposure record is the reason it is covered at all, and the reason it is covered only that way.
• Epitalon rests largely on in vitro telomerase work (PMID 12937682) and rodent studies from a single research tradition. It is the thinnest file of the six.

TB-500 deserves its own paragraph, because this is where most writing on the subject goes wrong. TB-500 is a 7-amino-acid fragment — Ac-Leu-Lys-Lys-Thr-Glu-Thr-Gln-OH, molecular weight 949.1. Thymosin β4, the protein it is derived from, is 43 amino acids. The human randomised trials people cite for "TB-500" — the phase 2 severe dry eye trial (PMID 25826322) and the European venous ulcer study (PMID 17495250) — used full-length thymosin β4, not the fragment. HHS's own appendix is careful here where marketing is not: it says the parent protein has a controlled human safety record, and that the fragment is rapidly truncated in human serum. A safety record for a 43-residue protein is not a safety record for a 7-residue piece of it.

It is a draft, and it is being challenged

Evidence tier: Tier 1 for the docket and comment window. The petition's claims are the petitioner's allegations, not findings, and we take no position on them.

Two things make this less settled than the coverage implies.

It is a draft with an unusually short comment window. Written comments close two weeks after publication — around 13 November 2026 — on Docket No. HHS-OASH-2026-0496. HHS says public comments may supply additional evidence for the FDA to consider in the actual rulemaking.

A citizen petition is already in. The Partnership for Safe Medicines filed a petition in the week before the announcement urging the FDA to disregard the committee's vote and block compounding of unapproved peptides. Its argument has two limbs: that the scientific evidence is insufficient, and that the committee was constituted in violation of the Federal Advisory Committee Act and the Ethics in Government Act — the federal conflict-of-interest rules for advisory proceedings. Its executive director's framing is that the decision "leaves Americans in a grey area as to whether peptides are safe or not."

We take no position on the petition's merits. We note only that the policy's durability is an open question, and that a policy which "does not establish any rights for any person" is a thinner foundation than a rule.

The retail layer forming on top of it

Evidence tier: Tier 5 for the commercial details. Pricing, dates and product lineups come from a company's own published materials and can change; we have not independently verified them.

Within days, prescription peptide subscriptions appeared, and their design tells you the route limits are already shaping products.

The first mover is Superpower, which launched a membership pairing a prescribed peptide with a 40-biomarker blood panel and clinician messaging. Pricing is published at $149 a month for BPC-157 and TB-500 and $199 for MOTS-c, charged up front as a preorder against a late-November target ship date "pending pharmacy confirmation", with a refund if no prescription is issued. Epitalon, an oral BPC product and a Semax nasal spray are on a waitlist.

Read that lineup against Appendix B and it is visibly policy-aware: Semax appears as a nasal spray rather than an injection, BPC-157 appears in both injectable and oral form, and KPV — covered only topically and orally — is absent altogether. Whoever built the catalogue read the appendix.

The company states plainly that the products are not FDA-approved, that the peptides are investigational, and that a prescription is not guaranteed. That is more candid than most of this market. It does not change the underlying position: a patient on this route is taking a compounded, un-reviewed drug under an interim policy that is still in draft.

What genuinely is new is the structure. Until now the practical choice was a research-chemical vendor with no prescriber, no pharmacy and no accountability. A licensed prescriber, a US pharmacy, an FDA-registered API with a certificate of analysis and a MedWatch reporting obligation is a different risk profile — not a safe one, a documented one. That is precisely the displacement HHS said it was aiming for, and it is the strongest argument for the policy.

It is not, and we want to be exact about this, evidence that any of these six peptides works.

What comes next

Evidence tier: Tier 1 for the announced agenda; anything about outcomes is forecast, not fact.

The advisory committee meets again before February 2027 to consider five further peptides. This is where the "five peptides" figure comes from:

GHK-Cu is the one to watch. It was already moved onto the FDA's Category 1 list in May 2026, which puts it in a different and more permissive position than the other four before the meeting even happens.

What would change our framing

Evidence tier: Not applicable. This lists conditions that would change our view; it makes no evidence claim.

• A final rule. If the FDA adds some or all six to the 503A bulks list through notice-and-comment rulemaking, enforcement discretion stops mattering and these become ordinary compoundable substances. That is the outcome that would make this durable.
• Withdrawal or narrowing after comment. The window closes around 13 November and the policy is explicitly revisitable.
• A successful FACA or EIGA challenge to the committee's composition, which would reach back to the July vote the policy rests on.
• A safety signal. The policy's MedWatch condition exists to produce one, and HHS has reserved the right to act on it. The first real post-market surveillance data on these peptides is about to exist, which is itself a change worth welcoming.
• An actual efficacy trial. None of the above touches whether these work. Nothing in this policy requires anyone to find out.

Limitations

This is an educational summary of a draft regulatory document, not legal or medical advice, and US law only.

• It is a draft. The policy can be narrowed, withdrawn or replaced after the comment window, and we have summarized the version as published.
• Retail and pricing details come from company materials and move quickly; check them directly.
• We take no position on the citizen petition's legal claims or on the clinical merits of the six peptides beyond what the cited literature shows.
• Compounded drugs are not FDA-reviewed for safety, effectiveness or quality, whatever the enforcement posture.
• Marko Maal, MSc Pharmacy reviewed this article. Reviewer attribution does not constitute a doctor-patient relationship.

The bottom line

HHS's draft policy is a statement that it does not intend to enforce, under ten conditions, against compounding six specific peptides in specific forms and routes. It is not approval, it is not the bulks list, and it adds no efficacy evidence. Its practical effect is to make a documented, prescriber-and-pharmacy route available while the grey-market route stays unchanged, and that is the best argument for it. Its limits are just as real: it is a draft, it is contested, and the route and single-ingredient conditions exclude much of what people actually use. Read Appendix B before assuming a product is covered.

Related on this site

• Are peptides legal in 2026?
• BPC-157 and the FDA Category 2 status
• Compounded GLP-1s: 503A and 503B explained
• Khavinson peptide bioregulators (the Epitalon background)
• Our evidence-tier framework